Aflibercept high-dose (8mg) related intraocular inflammation (IOI) – a case series

Aflibercept high-dose (8mg) related intraocular inflammation (IOI) – a case series

Abstract Background Monitoring for potential inflammatory events following intravitreal anti-vascular endothelial factor (VEGF) injection is crucial with the use of new agents such as aflibercept 8 mg. Despite a safety profile comparable to aflibercept 2 mg in pivotal and phase 3 studies, reporting...

Full description

Saved in:
Bibliographic Details
Main Authors: Laura Hoffmann, Stephan Michels, Chiara Eandi, Muntadher Al Karam, Eva C. de Oliveira Figueiredo, Katja Hatz
Format: Article
Language:English
Published: BMC 2024-12-01
Series:BMC Ophthalmology
Subjects:
Adverse event
Aflibercept 8 mg
Intraocular inflammation
High dose
Anti-VEGF
Online Access:https://doi.org/10.1186/s12886-024-03788-w
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12886-024-03788-w

Similar Items